Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 ...
Hosted on MSN13d
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
Yahoo Finance7d
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.
Business Insider11d
Vertex Pharmaceuticals: Buy Rating Despite LSR Trial Setback, Future Prospects Remain Strong
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $555.00. Discover top-rated stocks from ...
Vertex Pharmaceuticals price target lowered to $520 from $566 at BMO Capital
BMO Capital lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $566 but keeps an Outperform rating on the shares.